RxDoctor Payments Data

John Sunew, MD

Interventional Cardiology · Katy, TXNPI 1932147303

Payments from drug & device makers

$8,667in general payments, 2019–2025

Across 264 payments — averaging $32.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • EKOS Corporation$1K
  • Amgen$934
  • Johnson & Johnson$642
  • Novartis$581
  • Boston Scientific$350
  • plus $3K from 24 others

What the payments were for

  • Speaking & faculty fees$1,95022%
  • Travel & lodging$5917%
  • Food & beverage$6,09970%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,667 in reported general payments places this provider in the 40th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$739,367
Medicare patients
925
Services billed
4,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$391,890
XareltoRivaroxaban171$187,189
EntrestoSacubitril/Valsartan50$81,835
Repatha SureclickEvolocumab57$52,863
Repatha SyringeEvolocumab22$21,758
Metoprolol Succinate568$6,769
Ezetimibe267$6,521
Atorvastatin Calcium586$6,387
Rosuvastatin Calcium342$5,706
BrilintaTicagrelor12$4,724
Flecainide Acetate118$4,469
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,926
Amiodarone Hcl159$3,531
Carvedilol366$3,085
Losartan Potassium247$2,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$173$391,890318 claims
Johnson & JohnsonXarelto$642$187,189171 claims
NovartisEntresto$581$81,83550 claims
AstraZenecaBrilinta$313$4,72412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →